scholarly journals Interfocal heterogeneity challenges the clinical usefulness of molecular classification of primary prostate cancer

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Kristina Totland Carm ◽  
Andreas M. Hoff ◽  
Anne Cathrine Bakken ◽  
Ulrika Axcrona ◽  
Karol Axcrona ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Classification ◽  
Primary Diagnosis ◽  
The Cancer Genome Atlas ◽  
Clinical Usefulness ◽  
Whole Exome ◽  
Primary Prostate Cancer ◽  
Cancer Genome Atlas ◽  
Prostate Cancers

Abstract Prostate cancer is a highly heterogeneous disease and typically multiple distinct cancer foci are present at primary diagnosis. Molecular classification of prostate cancer can potentially aid the precision of diagnosis and treatment. A promising genomic classifier was published by The Cancer Genome Atlas (TCGA), successfully classifying 74% of primary prostate cancers into seven groups based on one cancer sample per patient. Here, we explore the clinical usefulness of this classification by testing the classifier’s performance in a multifocal context. We analyzed 106 cancer samples from 85 distinct cancer foci within 39 patients. By somatic mutation data from whole-exome sequencing and targeted qualitative and quantitative gene expression assays, 31% of the patients were uniquely classified into one of the seven TCGA classes. Further, different samples from the same focus had conflicting classification in 12% of the foci. In conclusion, the level of both intra- and interfocal heterogeneity is extensive and must be taken into consideration in the development of clinically useful molecular classification of primary prostate cancer.

scholarly journals Accurate diagnosis of prostate cancer using logistic regression

Open Medicine ◽  
2021 ◽  
Vol 16 (1) ◽  
pp. 459-463
Author(s):  
Arash Hooshmand
Keyword(s):  
Prostate Cancer ◽  
Logistic Regression ◽  
Tissue Expression ◽  
The Cancer Genome Atlas ◽  
Sequencing Data ◽  
Whole Exome ◽  
Whole Exome Sequencing Data ◽  
Cancer Genome Atlas ◽  
High Level

Abstract A new logistic regression-based method to distinguish between cancerous and noncancerous RNA genomic data is developed and tested with 100% precision on 595 healthy and cancerous prostate samples. A logistic regression system is developed and trained using whole-exome sequencing data at a high-level, i.e., normalized quantification of RNAs obtained from 495 prostate cancer samples from The Cancer Genome Atlas and 100 healthy samples from the Genotype-Tissue Expression project. We could show that both sensitivity and specificity of the method in the classification of cancerous and noncancerous cells are perfectly 100%.

scholarly journals PO-311 Multifocality complicates molecular classification of primary prostate cancer

2018 ◽  
Author(s):  
K Carm ◽  
S Zhao ◽  
AC Bakken ◽  
B Johannessen ◽  
AM Hoff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Molecular Classification ◽  
Primary Prostate Cancer

scholarly journals Automatic Classification of Prostate Cancer Gleason Scores from Digitized Whole Slide Tissue Biopsies

2018 ◽  
Author(s):  
Hongming Xu ◽  
Sunho Park ◽  
Tae Hyun Hwang
Keyword(s):  
Prostate Cancer ◽  
Texture Features ◽  
The Cancer Genome Atlas ◽  
Support Vector ◽  
Pixel Intensity ◽  
Gleason Grading ◽  
Slide Image ◽  
Cancer Genome Atlas ◽  
Automatic Technique

AbstractHistological Gleason grading of tumor patterns is one of the most powerful prognostic predictors in prostate cancer. However, manual analysis and grading performed by pathologists are typically subjective and time-consuming. In this paper, we propose an automatic technique for Gleason grading of prostate cancer from H&E stained whole slide biopsy images using a set of novel completed and statistical local bi-nary pattern (CSLBP) descriptors. First the technique divides the whole slide image into a set of small image tiles, where salient tumor tiles with high nuclei densities are selected for analysis. The CSLBP texture features that encode pixel intensity variations from circularly surrounding neighborhoods are then extracted from salient image tiles to characterize different Gleason patterns. Finally, CSLBP texture features computed from all tiles are integrated and utilized by the multi-class support vector machine (SVM) that assigns patient biopsy with different Gleason score of 6, 7 or ≥8. Experiments have been performed on 312 different patient cases selected from the cancer genome atlas (TCGA) and have achieved more than 79% classification accuracies, which is superior to state-of-the-art textural descriptors for prostate cancer Gleason grading.

scholarly journals RNA m6A Methylation Regulators Multi-Omics Analysis in Prostate Cancer

2021 ◽  
Vol 12 ◽  
Author(s):  
Hao Su ◽  
Yutao Wang ◽  
Hongjun Li
Keyword(s):  
Prostate Cancer ◽  
Rna Splicing ◽  
Methylation Status ◽  
Copy Number Variations ◽  
The Cancer Genome Atlas ◽  
Rna Modification ◽  
Migration And Invasion ◽  
Cancer Genome Atlas ◽  
Prostate Cancers

RNA N6-methyladenosine (m6A) methylation is known to be the most popular RNA modification in animals. Many research reports have elaborated on the effects of m6A regulators in medical practice, such as diagnosis, prognosis, and treatment. M6A modification has evident impacts on many aspects of RNA metabolism, just like RNA splicing, processing, translation, and stability. M6A also has a magnificent role in numerous types of cancers. We analyzed the prostate cancer datasets, from The Cancer Genome Atlas (TCGA) database, for every recognized m6A regulator in their gene expression, DNA methylation status and copy number variations (CNVs). We also systematically analyzed the relationship between different m6A regulators and the prognosis of prostate cancer. The results illustrated considerable differences in the expression of various m6A regulators between the prostate and normal cancer samples. At the same time, there were evident differences in the expression of various m6A regulators in prostate cancers with different Gleason scores. Subsequently, we determined CBLL1, FTO, YTHDC1, HNRNPA2B1 as crucial m6A regulators of prostate cancer. Premised on the expression of CBLL1, we also identified potential therapeutic agents for prostate cancer, and knockdown of HNRNPA2B1 prominently inhibited prostate cells migration and invasion in vitro experiment.

scholarly journals Predicted CD4+ T cell infiltration levels could indicate better overall survival in sarcoma patients

2021 ◽  
Vol 49 (1) ◽  
pp. 030006052098153
Author(s):  
Qing Bi ◽  
Yang Liu ◽  
Tao Yuan ◽  
Huizhen Wang ◽  
Bin Li ◽  
...  
Keyword(s):  
Overall Survival ◽  
T Cell ◽  
Survival Data ◽  
Tumor Infiltrating Lymphocytes ◽  
The Cancer Genome Atlas ◽  
Cell Infiltration ◽  
T Cell Infiltration ◽  
Whole Exome ◽  
Cancer Genome Atlas ◽  
Infiltrating Lymphocytes

Objective The role of tumor-infiltrating lymphocytes (TILs) has not yet been characterized in sarcomas. The aim of this bioinformatics study was to explore the effect of TILs on sarcoma survival and genome alterations. Methods Whole-exome sequencing, transcriptome sequencing, and survival data of sarcoma were obtained from The Cancer Genome Atlas. Immune infiltration scores were calculated using the Tumor Immune Estimation Resource. Potential associations between abundance of infiltrating TILs and survival or genome alterations were examined. Results Levels of CD4+ T cell infiltration were associated with overall survival of patients with pan-sarcomas, and higher CD4+ T cell infiltration levels were associated with better survival. Somatic copy number alterations, rather than mutations, were found to correlate with CD4+ T cell infiltration levels. Conclusions This data mining study indicated that CD4+ T cell infiltration levels predicted from RNA sequencing could predict sarcoma prognosis, and higher levels of CD4+ T cells infiltration indicated a better chance of survival.

scholarly journals Promoter Methylation of PRKCB, ADAMTS12, and NAALAD2 Is Specific to Prostate Cancer and Predicts Biochemical Disease Recurrence

2021 ◽  
Vol 22 (11) ◽  
pp. 6091
Author(s):  
Kristina Daniunaite ◽  
Arnas Bakavicius ◽  
Kristina Zukauskaite ◽  
Ieva Rauluseviciute ◽  
Juozas Rimantas Lazutka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Clinical Practice ◽  
Promoter Methylation ◽  
Disease Recurrence ◽  
The Cancer Genome Atlas ◽  
Cancer Dataset ◽  
Protein Coding ◽  
Diagnosis And Prognosis ◽  
Genome Wide ◽  
Cancer Genome Atlas

The molecular diversity of prostate cancer (PCa) has been demonstrated by recent genome-wide studies, proposing a significant number of different molecular markers. However, only a few of them have been transferred into clinical practice so far. The present study aimed to identify and validate novel DNA methylation biomarkers for PCa diagnosis and prognosis. Microarray-based methylome data of well-characterized cancerous and noncancerous prostate tissue (NPT) pairs was used for the initial screening. Ten protein-coding genes were selected for validation in a set of 151 PCa, 51 NPT, as well as 17 benign prostatic hyperplasia samples. The Prostate Cancer Dataset (PRAD) of The Cancer Genome Atlas (TCGA) was utilized for independent validation of our findings. Methylation frequencies of ADAMTS12, CCDC181, FILIP1L, NAALAD2, PRKCB, and ZMIZ1 were up to 91% in our study. PCa specific methylation of ADAMTS12, CCDC181, NAALAD2, and PRKCB was demonstrated by qualitative and quantitative means (all p < 0.05). In agreement with PRAD, promoter methylation of these four genes was associated with the transcript down-regulation in the Lithuanian cohort (all p < 0.05). Methylation of ADAMTS12, NAALAD2, and PRKCB was independently predictive for biochemical disease recurrence, while NAALAD2 and PRKCB increased the prognostic power of multivariate models (all p < 0.01). The present study identified methylation of ADAMTS12, NAALAD2, and PRKCB as novel diagnostic and prognostic PCa biomarkers that might guide treatment decisions in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document